Cardiometabolic Disease

Objectives of the CRT meeting in Cardiometabolic Disease

1. Understanding the scope of cardiometabolic disease along life cycle, common pathophysiologic basis, classical and emerging risk factors, global and precision risk prediction (biomarkers, imaging, omics and AI)
2. Approaching determinants of cardiometabolic health – role of genetics, epigenetics, environment and human behavior
3. Focusing intervention on cardiometabolic disease prevention, in line with the EU CV plan – lifestyle changes implementation, novel therapies and integrated care
4. Identification of gaps in cardiometabolic landscape
5. Proposals for implementation projects in Europe
6. Imperative for prevention: Foreseeing the future of cardiometabolic disease management and the role of AI support

Day 1 –  18 March 2026 (13:30 – 18:40, Room: Bratislava)  

• 13:30-13:35 –   Welcome from the CRT Chairpersons  
  Speakers:   Cecilia Linde and Bettina Kraus (BI) 
  •   13:35 -15:15    – Session 1.1 - The Evolving picture of cardiometabolic disease  
    Moderated by:   Ana Abreu and Prodromos Anthopoulos (Cytokinetics)  
  • 13:35-13:45  –   EU CV health plan: cardiometabolic disease in perspective  
    Speaker: Thomas F Lüscher 
  • 13:45-13:55  –     Patterns, causes and risk factors (classical and emergent) of cardiometabolic disease  
    Speaker: Francesco Cosentino
  • 13:55-14:05 -  Shared pathophysiology for diverse clinical presentations: inflammation, adipose tissue biology, insulin resistance
  • Speaker:   Maria Marketou 
  • 14:05-14:15 - Global and precision risk prediction along life cycle; biomarkers,imaging,omics,and machine learning 
  • Speaker: Emanuelle Di Angelantonio 
  •   14:05-14:15 – Panel Discussion
  • 15:15 -18:30 SESSION 1.2 – Determinants of cardiometabolic health
  • Moderated by: John Deanfield and Monika Gratzke (Daiichi-Sankyo)  
  • 13:35-13:45  –  The role of environment
    Speaker: Paul Dendale
  • 15:25-15:35  –  The role of human behavior
    Speaker: Lis Neubeck
  • 15:35-15:45  –  How to deal with the Determinants of Cardiometabolic Health
    Speaker: Massimo Piepoli 

• 15:45 -16:15 – Panel Discussion
• 16:20–17:20 – Breakout Sessions
  Identify and deal with the gaps in cardiometabolic disease
  • Group 1 – Room Bratislava
    Prevention and treatment gap: Lack of implementation
    Lead: Matthias Wilhelm
    Rapporteur: Michael Madigan (ESC Patient Forum)
  • Group 2 – Room Pressburg
    Research gap: What is unknown about new drugs’ effect
    Lead: Maddalena Lettino
    Rapporteur: Ahmad Alhussein (BI)
  • Group 3 – Room Istropolis
    Health equity gap: Challenges for access to prevention and treatment in different population sectors
    Lead: Paul Dendale
    Rapporteur: Massimo Piepoli
• 17:20–17:30 – Report from breakout session 1 (Rapporteur: Michael Madigan)
• 17:30–17:40 – Report from breakout session 2 (Rapporteur: Ahmad Alhussein)
• 17:40–17:50 – Report from breakout session 3 (Rapporteur: Massimo Piepoli)
• 17:50–18:20 – Panel Discussion
• 18:20–18:30 – Wrap‑up and Summary Day 1
  Outlook to Day 2
  Speakers: Ana Abreu, Katja Rohwedder (Bayer)
• End of Day 1
• 19:30 – Aperitif + Dinner

Day 2 – 19 March 2026 (08:30–12:30, Room: Bratislava)

• 08:30–08:40 – Summary of Day 1
  Speakers: Ana Abreu, John Deanfield
• 08:40–10:40 – Session 2.1:
  Intervention focus on cardiometabolic disease
  Moderated by: Dr Monika Gratzke (Daiichi-Sankyo) & Dr Katja Rohwedder (Bayer)
  • 08:40–08:50 – Lifestyle changes for global prevention and implementation
    Speaker: Ana Abreu
  • 08:50–09:00 – Novel therapies and integrated care models
    Speaker: John Deanfield
  • 09:00–09:20 – Panel Discussion
  • 09:20–10:10 – Breakout Sessions
    Innovative research projects design in cardiometabolic landscape
    • Group 4 – Room Bratislava
      Topic: Obesity and/or diabetes
      Lead: Cecilia Linde
      Rapporteur: Klaus Kuhlbusch (Roche Pharma)
    • Group 5 – Room Pressburg
      Chronic Kidney Disease and/or Hypertension
      Lead: Eva Gerdts
      Rapporteur: Maria Ripa (Novonordisk)
    • Group 6 – Room Istropolis
      Role of the gut and liver on cardiometabolic risk profile
      Lead: Tomasz Guzik
      Rapporteur: Daniela Fliegner (Pfizer)
  • 10:10–10:20 – Report & comments from breakout session 4
    Rapporteur: Klaus Kuhlbusch
  • 10:20–10:30 – Report & comments from breakout session 5
    Rapporteur: Maria Ripa
  • 10:30–10:40 – Report & comments from breakout session 6
    Rapporteur: Daniela Fliegner(Pfizer)
• 11:10–12:30 – Session 2.2:
  What will the future bring: a bird’s‑eye view
  Moderated by: Prodromos Anthopoulos (Cytokinetics), John Deanfield, Ana Abreu
  • 11:10–11:20 – Prevention rather than cure: A call for action
    Speaker: Constantinos Davos
  • 11:20–11:30 – Patient’s perspective
    Speaker: Konstantina Boumaki
  • 11:30–11:40 – AI transforming the future of cardiometabolic disease
    Speaker: Rubens Casado Arroy (via Zoom)
  • 11:40–12:20 – Panel Discussion & Next Steps
  • 12:20–12:30 – Wrap‑up & Conclusion
    Speakers: Cecilia Linde, Bettina Kraus (BI)
• End of Day 2
• 12:30 – Buffet lunch and departures